University of Cambridge, Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Hills Road, Cambridge CB2 OXZ, UK.
Curr Biol. 2012 Sep 25;22(18):1659-66. doi: 10.1016/j.cub.2012.07.034. Epub 2012 Aug 2.
The breast and ovarian cancer suppressor BRCA1 is essential for cellular responses to DNA damage. It heterodimerizes with BARD1 to acquire an E3 ubiquitin (Ub) ligase activity that is often compromised by cancer-associated mutations. Neither the significance of this activity to damage responses, nor a relevant in vivo substrate, is clear.
We have separated DNA-damage responses requiring the BRCA1 E3 ligase from those independent of it, using a gene-targeted point mutation in vertebrate DT40 cells that abrogates BRCA1's catalytic activity without perturbing BARD1 binding. We show that BRCA1 ubiquitylates claspin, an essential coactivator of the CHK1 checkpoint kinase, after topoisomerase inhibition, but not DNA crosslinking by mitomycin C. BRCA1 E3 inactivation decreases chromatin-bound claspin levels and impairs homology-directed DNA repair by interrupting signal transduction from the damage-activated ATR kinase to its effector, CHK1.
Our findings identify claspin as an in vivo substrate for the BRCA1 E3 ligase and suggest that its modification selectively triggers CHK1 activation for the homology-directed repair of a subset of genotoxic lesions. This mechanism unexpectedly defines an essential but selective function for BRCA1 E3 ligase activity in cellular responses to DNA damage.
乳腺癌和卵巢癌抑制因子 BRCA1 对细胞对 DNA 损伤的反应至关重要。它与 BARD1 异二聚化,获得 E3 泛素(Ub)连接酶活性,该活性通常因癌症相关突变而受损。这种活性对损伤反应的意义,以及相关的体内底物,都不清楚。
我们使用脊椎动物 DT40 细胞中的基因靶向点突变,将需要 BRCA1 E3 连接酶的 DNA 损伤反应与不依赖它的反应分离,该突变使 BRCA1 的催化活性丧失,而不干扰 BARD1 的结合。我们表明,BRCA1 在拓扑异构酶抑制剂后泛素化 claspin,claspin 是 CHK1 检查点激酶的必需共激活因子,但 mitomycin C 引起的 DNA 交联则不会。BRCA1 E3 失活会降低染色质结合的 claspin 水平,并通过中断损伤激活的 ATR 激酶与其效应物 CHK1 之间的信号转导,损害同源定向 DNA 修复。
我们的发现将 claspin 鉴定为 BRCA1 E3 连接酶的体内底物,并表明其修饰选择性地触发 CHK1 激活,以进行特定类型的遗传毒性损伤的同源定向修复。这种机制出人意料地定义了 BRCA1 E3 连接酶活性在细胞对 DNA 损伤反应中的必需但选择性功能。